Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings, Inc. - Common Stock (NQ: BPTH )

1.040 -0.070 (-6.31%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Path Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22
Dallas, Texas--(Newsfile Corp. - April 10, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): The... 
Via Newsfile
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
A Preview Of Bio-Path Holdings's Earnings
Via Benzinga
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides Clinical and Operational Update
Company Expects to Achieve Several Near-Term Clinical Milestones 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22
Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path... 
Via Newsfile
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Q3 2022 Earnings Conference Call On November 15, 2022 At 08:30 AM ET
Bio-Path Holdings (NASDAQ:BPTH) will host a conference call at 08:30 AM ET on November 15, 2022, to discuss Q3 2022 earnings results. How to Attend Bio-Path Holdings (BPTH) Conference Call Follow this... 
Via Benzinga
Analyzing Bio-Path Holdings's Short Interest
Bio-Path Holdings's (NASDAQ:BPTH) short percent of float has fallen 10.42% since its last report. The company recently reported that it has 34 thousand shares sold short, which is 0.43% of all regular... 
Via Benzinga
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cell’s Ability to Produce Bcl-2 Protein 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH)
Dallas, Texas--(Newsfile Corp. - September 30, 2022) - Bio-Path Holdings, Inc. (Nasdaq: BPTH): The full report can be accessed by... 
Via Newsfile
Bio-Path Holdings: Q2 Earnings Insights
  Bio-Path Holdings (NASDAQ:BPTH) reported its Q2 earnings results on Tuesday, August 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For August 16, 2022
Companies Reporting Before The Bell • Stronghold Digital Mining (NASDAQ:SDIG) is projected to report earnings for its second quarter. 
Via Benzinga
Earnings Outlook For Bio-Path Holdings
  Bio-Path Holdings (NASDAQ:BPTH) is set to give its latest quarterly earnings report on Tuesday, 2022-08-16. Here's what investors need to know before the announcement. 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Telsey Advisory Group cut the price target for Bath & Body Works, Inc. (NYSE: BBWI) from $70 to $60. Bath & Body Works shares fell 6.9% to $40.00 in pre-market trading. 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Bio-Path Holdings: Q1 Earnings Insights
Bio-Path Holdings (NASDAQ:BPTH) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 17, 2022
Companies Reporting Before The Bell • On Holding (NYSE:ONON) is likely to report earnings for its first quarter. 
Via Benzinga
A Preview Of Bio-Path Holdings's Earnings
Bio-Path Holdings (NASDAQ:BPTH) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Bio-Path... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Why Bio-Path Holdings Shares Are Rising After Hours
Bio-Path Holdings Inc (NASDAQ: BPTH) shares are trading higher in Tuesday's after-hours session following the company's BP1003 data presentation at the 2022 American Association for Cancer Research... 
Via Benzinga
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of Conditional Approval For COVID Vaccine Candidate In... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.